

**The Royal Marsden NHS Foundation Trust
Drug & Therapeutic Committee minutes
20th December 2019**

Present: Consultant Breast and AOS (deputy chair)
Drug Resource Manager (secretary)
Consultant Palliative Medicine
Governance & Medication Safety Lead Pharmacist
Clinical Oncology Consultant
DDU fellow (Medical Oncology)
Consultant in Medical Oncology - Sarcoma
Consultant Microbiologist

In attendance:

1. Minutes of the November meeting

a. Minutes – approved.

2. Conflict of Interest

Provided and agreed.

3. NICE Guidance update

No NICE guidance published since last meeting.

4. One off drug use requests

1. Venetoclax in relapsed/refractory AML.
2. Palbociclib in combination with letrozole in locally advanced Breast ca.
3. Olaparib (via CUP) in patient with allergy to carboplatin (Breast ca.).
4. Abemaciclib in 1st line ER +ve Breast ca.
5. BLU667 (pralsetinib) (via CUP) in NSCLC.
6. Anakinra in Haemophaglytic Lymphohistiocytosis.
7. Brincidofovir (via CUP) in persistant adenoviraemia.
8. Sorafenib (via CUP) in relapsed refractory FLT3 +ve AML.

All requests approved.

5. Pralsetinib (BLU667) (via compassionate supply). Presented by the Lung unit.

Proposed for use in patients diagnosed with NSCLC or MTC, who have a RET fusion or RET mutation, have exhausted available standard therapies, and who are ineligible for or are otherwise unable to access a clinical trial in line with the compassionate supply program.

Action:

Approved.

6. Lorlatinib (via compassionate supply). Presented by Lung unit

Proposed for use in the treatment of adult patients with anaplastic lymphoma kinase (ALK)-

positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed, in line with the compassionate supply program.

Action:

Approved.

7. Tramentanib in ovarian cancer. Presented by the Gynaecology unit.

Proposed for use for low grade serous ovarian cancer in which there are no effective treatments and no established standard of care.

Action:

Approved.

8. Cisplatin hydration regimen. Presented by Pharmacy.

Developed in order to standardise the hydration regimens used at the trust and to make them more efficient with regard to the duration they are required to be given over.

Action:

Approved.

9. Dermatology Formulary. Presented by Pharmacy.

Developed by pharmacy and the dermatology consultants in order to ensure all the required medicines are available and also to provide detail of access to the medicines i.e. if they are standardly kept in pharmacy or they are required to be procured on an individual patient basis.

Action:

Approved.

10. Melanoma unit – pharmacy & nurse led clinics. \presented by Pharmacy & Nursing
Report presented to the committee highlighting impact of the clinics on the service provision.

Action:

n/a

11. CAR-T service overview. Presented by Pharmacy.

An overview of the service requirements and anticipated provision was provided.

Action:

n/a

12. PGD: BCG vaccine. Presented by Pharmacy (on behalf of Occ. Health).

Action:

Approved.

13. SOP for Named Patient & Compassionate Supply Programs. Presented by Pharmacy.

Developed to provide guidance to clinicians and pharmacists regarding the local processes to be followed for the initiation and re-supply of medicines obtained via compassionate supply programmes.

Action:

Approved.

14. AOB

Date of the Next Meeting:

Thursday 29th of January (pm), 15:00 – 17:00

Minutes Approved	DTC chair: Thursday 29 th January 2020
------------------	---

Date of next meeting 29 th January 2020.
